Stéphane Roze

2.4k total citations
73 papers, 1.7k citations indexed

About

Stéphane Roze is a scholar working on Endocrinology, Diabetes and Metabolism, Surgery and Economics and Econometrics. According to data from OpenAlex, Stéphane Roze has authored 73 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 46 papers in Endocrinology, Diabetes and Metabolism, 23 papers in Surgery and 21 papers in Economics and Econometrics. Recurrent topics in Stéphane Roze's work include Diabetes Treatment and Management (38 papers), Diabetes Management and Research (37 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Stéphane Roze is often cited by papers focused on Diabetes Treatment and Management (38 papers), Diabetes Management and Research (37 papers) and Health Systems, Economic Evaluations, Quality of Life (19 papers). Stéphane Roze collaborates with scholars based in United States, Switzerland and France. Stéphane Roze's co-authors include William J. Valentine, Andrew Palmer, Giatgen A. Spinas, Morten Lammert, Michael E. Minshall, V. Foos, Jayne Smith‐Palmer, Joshua Ray, Simona de Portu and Peter Lynch and has published in prestigious journals such as Journal of Clinical Oncology, Diabetes Care and Kidney International.

In The Last Decade

Stéphane Roze

71 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Stéphane Roze United States	21	1.1k	373	340	273	242	73	1.7k
Joel E. Segel United States	18	457 0.4×	265 0.7×	232 0.7×	57 0.2×	207 0.9×	61	1.4k
Maria Chiara Rossi Italy	24	1.1k 1.0×	211 0.6×	47 0.1×	95 0.3×	422 1.7×	65	1.6k
Siew Pheng Chan Malaysia	22	600 0.5×	300 0.8×	80 0.2×	51 0.2×	260 1.1×	69	1.4k
Xavier Cos Spain	17	739 0.7×	136 0.4×	53 0.2×	80 0.3×	174 0.7×	80	1.1k
Mats Bojestig Sweden	15	512 0.5×	180 0.5×	60 0.2×	252 0.9×	51 0.2×	19	979
Emma Eggleston United States	17	339 0.3×	175 0.5×	106 0.3×	79 0.3×	213 0.9×	24	1.2k
Maria Constantino Australia	17	817 0.7×	332 0.9×	25 0.1×	253 0.9×	199 0.8×	49	1.5k
Ronald Horswell United States	25	551 0.5×	219 0.6×	52 0.2×	52 0.2×	222 0.9×	69	1.4k
P Royle United Kingdom	6	282 0.3×	268 0.7×	102 0.3×	198 0.7×	207 0.9×	6	1.0k
Fernando Álvarez Guisasola Spain	17	688 0.6×	206 0.6×	32 0.1×	106 0.4×	213 0.9×	64	1.2k

Countries citing papers authored by Stéphane Roze

Since Specialization

Citations

This map shows the geographic impact of Stéphane Roze's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stéphane Roze with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stéphane Roze more than expected).

Fields of papers citing papers by Stéphane Roze

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stéphane Roze. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stéphane Roze. The network helps show where Stéphane Roze may publish in the future.

Co-authorship network of co-authors of Stéphane Roze

This figure shows the co-authorship network connecting the top 25 collaborators of Stéphane Roze. A scholar is included among the top collaborators of Stéphane Roze based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stéphane Roze. Stéphane Roze is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Charleer, Sara, John J. Isitt, Stéphane Roze, et al.. (2024). Cost–utility analysis of Dexcom G6 real-time continuous glucose monitoring versus FreeStyle Libre 1 intermittently scanned continuous glucose monitoring in adults with type 1 diabetes in Belgium. Diabetologia. 67(4). 650–662. 1 indexed citations

2.

Delmas, Clément, et al.. (2022). Budget Impact Analysis of Impella CP® Utilization in the Management of Cardiogenic Shock in France: A Health Economic Analysis. Advances in Therapy. 39(3). 1293–1309. 8 indexed citations

3.

Roze, Stéphane, et al.. (2022). A Review of Overall Survival Extrapolations of Immune-Checkpoint Inhibitors Used in Health Technology Assessments by the French Health Authorities. International Journal of Technology Assessment in Health Care. 38(1). e28–e28. 3 indexed citations

4.

Guyader, Alexandre Le, Mathieu Pernot, Clément Delmas, et al.. (2021). Budget Impact Associated with the Introduction of the Impella 5.0® Mechanical Circulatory Support Device for Cardiogenic Shock in France. ClinicoEconomics and Outcomes Research. Volume 13. 53–63. 5 indexed citations

5.

Roze, Stéphane, et al.. (2020). Long-Term Cost-Effectiveness the Dexcom G6 Real-Time Continuous Glucose Monitoring System Compared with Self-Monitoring of Blood Glucose in People with Type 1 Diabetes in France. Diabetes Therapy. 12(1). 235–246. 18 indexed citations

6.

Doubova, Svetlana V., et al.. (2019). Cost-effectiveness of the use of the continuous subcutaneous insulin infusion pump versus daily multiple injections in type 1 diabetes adult patients at the Mexican Institute of Social Security. Cost Effectiveness and Resource Allocation. 17(1). 19–19. 6 indexed citations

7.

Petitjean, Audrey, Jayne Smith‐Palmer, William J. Valentine, B. Téhard, & Stéphane Roze. (2019). Cost-effectiveness of bevacizumab plus paclitaxel versus paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer in specialist oncology centers in France. BMC Cancer. 19(1). 140–140. 8 indexed citations

8.

Kotapati, Srividya, et al.. (2019). Modelling Survival of Patients Treated with Adjuvant Nivolumab Who Have Melanoma with Lymph Node Involvement or Metastatic Disease After Complete Resection. PharmacoEconomics - Open. 4(2). 343–351. 4 indexed citations

9.

Roze, Stéphane, et al.. (2019). Cost-Effectiveness of Sensor-Augmented Insulin Pump Therapy Versus Continuous Insulin Infusion in Patients with Type 1 Diabetes in Turkey. Diabetes Technology & Therapeutics. 21(12). 727–735. 11 indexed citations

10.

Roze, Stéphane, et al.. (2019). Cost-Effectiveness of Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections in Patients with Poorly Controlled Type 2 Diabetes in Finland. Diabetes Therapy. 10(2). 563–574. 7 indexed citations

11.

Conget, Ignacio, et al.. (2018). Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología Diabetes y Nutrición. 65(7). 380–386. 10 indexed citations

12.

Conget, Ignacio, et al.. (2018). Cost-effectiveness analysis of sensor-augmented pump therapy with low glucose-suspend in patients with type 1 diabetes mellitus and high risk of hypoglycemia in Spain. Endocrinología Diabetes y Nutrición (English ed ). 65(7). 380–386. 1 indexed citations

13.

Basson, Mickaël, et al.. (2017). The Cost-effectiveness of Dulaglutide 1.5mg versus Exenatide QW for the Treatment of Patients with Type 2 Diabetes Mellitus in France. Diabetes Therapy. 9(1). 13–25. 12 indexed citations

14.

Durand‐Zaleski, Isabelle, Pascal Bilbault, Anne-Françoise Gaudin, et al.. (2016). Survie sans progression, survie globale et qualité de vie : quel intérêt au plan médicoéconomique en oncologie ?. Therapies. 71(1). 59–67. 1 indexed citations

15.

Smith‐Palmer, Jayne, Stéphane Roze, Peter Lynch, et al.. (2015). Project Baiterek: A Patient Access Program to Improve Clinical Outcomes and Quality of Life in Children with Type 1 Diabetes in Kazakhstan. Value in Health Regional Issues. 7. 74–79. 2 indexed citations

16.

Chaiyakunapruk, Nathorn, et al.. (2008). Cost-Effectiveness Analysis of Thiazolidinediones in Uncontrolled Type 2 Diabetic Patients Receiving Sulfonylureas and Metformin in Thailand. Value in Health. 11. S43–S51. 15 indexed citations

17.

Tucker, Daniel M., Andrew Palmer, William J. Valentine, Stéphane Roze, & Joshua Ray. (2006). Counting the costs of overweight and obesity: modeling clinical and cost outcomes. Current Medical Research and Opinion. 22(3). 575–586. 38 indexed citations

18.

Palmer, Andrew, William J. Valentine, Daniel M. Tucker, et al.. (2006). A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension. Current Medical Research and Opinion. 22(11). 2095–2100. 8 indexed citations

19.

Palmer, Andrew, Stéphane Roze, William J. Valentine, et al.. (2004). What Impact Would Pancreatic Beta-cell Preservation Have on Life Expectancy, Quality-adjusted Life Expectancy and Costs of Complications in Patients with Type 2 Diabetes? A Projection Using the CORE Diabetes Model. Current Medical Research and Opinion. 20(sup1). S59–S66. 13 indexed citations

20.

Palmer, Andrew, Lieven Annemans, Stéphane Roze, et al.. (2004). Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria. Kidney International. 67(93). S52–S54. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact